Suppr超能文献

干扰素β在有或无血清中和抗体的多发性硬化症患者中的药效学。

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.

作者信息

Scagnolari Carolina, Duda Petra, Bagnato Francesca, De Vito Gabriella, Alberelli Alessia, Lavolpe Vito, Girardi Enrico, Durastanti Valentina, Trojano Maria, Kappos Ludwig, Antonelli Guido

机构信息

Dept. of Experimental Medicine - Virology Section, La Sapienza University, Rome, Italy.

出版信息

J Neurol. 2007 May;254(5):597-604. doi: 10.1007/s00415-006-0332-7. Epub 2007 Apr 10.

Abstract

To analyze the in vivo biological effect of anti-interferon beta (IFN-beta) neutralizing antibodies (NABs), blood concentrations of neopterin, beta2microglobulin (Beta2-MG), mRNA-dependent myxovirusresistant protein A (MxA) and dsRNA-dependent protein kinase (PKR) were measured before (predose) and 24 hours after (postdose) IFN-beta administration in 49 patients with multiple sclerosis (MS) with (n = 25) and without (n = 24) NABs. The results indicated that predose levels of MxA-mRNA and PKR-mRNA were highly variable [coefficient of variation (CV) > 100%] among patients. A lower inter-individual variability was observed for pre-dose levels of Beta2-MG and neopterin (CVs of 29% and 44%, respectively). Significantly lower pre- and post-dose blood levels of IFN induced markers, except for postdose PKR-mRNA (p = 0.09), were seen in NAB+ compared with NAB-patients and between patients with high (> 200 t(1/10)) and low ( pound 200 t(1/10)) NAB titers. A significant inverse correlation between NAB titer and pre-dose levels of the above IFN-induced markers was found. In summary, our findings confirm that NABs affect absolute concentrations of IFN-beta induced markers and suggest that such an effect occurs in a titer-dependent manner.

摘要

为分析抗干扰素β(IFN-β)中和抗体(NABs)的体内生物学效应,在49例多发性硬化症(MS)患者中,分别于注射IFN-β前(给药前)和给药后24小时(给药后)测定了新蝶呤、β2微球蛋白(Beta2-MG)、mRNA依赖性抗粘病毒蛋白A(MxA)和dsRNA依赖性蛋白激酶(PKR)的血药浓度,其中25例患者有NABs,24例患者无NABs。结果表明,患者之间MxA-mRNA和PKR-mRNA的给药前水平高度可变[变异系数(CV)>100%]。给药前Beta2-MG和新蝶呤水平的个体间变异性较低(CV分别为29%和44%)。与无NABs的患者相比,以及在NAB滴度高(>200 t(1/10))和低(≤200 t(1/10))的患者之间,除给药后PKR-mRNA外(p = 0.09),有NABs的患者给药前和给药后的IFN诱导标志物血药水平显著较低。发现NAB滴度与上述IFN诱导标志物的给药前水平之间存在显著的负相关。总之,我们的研究结果证实NABs会影响IFN-β诱导标志物的绝对浓度,并表明这种影响以滴度依赖性方式发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验